<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226473</url>
  </required_header>
  <id_info>
    <org_study_id>ADO-MM-PAL8</org_study_id>
    <nct_id>NCT00226473</nct_id>
  </id_info>
  <brief_title>Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma</brief_title>
  <official_title>Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermatologic Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermatologic Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      The purpose of this multicenter study is to examine whether the proposed randomized treatment
      regime results in a significantly longer survival time and higher quality of life than any
      additionally applied multiple chemotherapy according to the CVD- scheme. So far neither
      established treatment regimes nor reliable data exist for the second-line chemotherapy of
      metastatic malignant melanoma. Patients are therefore mostly treated with single or multiple
      chemotherapeutics or/and immunomodulatory therapeutics. These regimes however imply often not
      only a higher toxicity but show rarely a response rate higher than 10%.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2001</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life analysis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate in study arm B</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analysis</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Metastatic Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin, Vindesine, Dacarbazine (drugs)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological diagnosis of metastatic melanoma (stage IV)

          -  progressive disease after first-line chemotherapy or immuno-chemotherapy

          -  Karnofsky-index &gt; 60%

          -  informed consent

        Exclusion Criteria:

          -  Uvea melanoma

          -  another primary malignancy except basal cell carcinoma or cervical carcinoma in situ

          -  severe and/or uncontrolled medical disease (diabetes mellitus, cardiac insufficiency)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Ulrich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Dermatology, University Otto von Guericke, Leipziger Strasse 44, D-39120 Magdeburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Axel Hauschild, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Dermatology, University of Kiel, Schittenhelmstrasse 5, D-24105 Kiel, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Mohr, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Dermatology, Medical Center Buxtehude, Krankenhausstrasse 1, D-21614 Buxtehude, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens Ulrich, MD</last_name>
    <phone>+49-391-6715428</phone>
    <email>jens.ulrich@medizin.uni-magdeburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Skin Cancer Unit, German Cancer Ressearch Center and Dept. of Dermatology, University Hospital of Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>D-68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Schadendorf, MD</last_name>
      <phone>+49-621-3832127</phone>
      <email>d.schadendorf@dkfz.de</email>
    </contact>
    <investigator>
      <last_name>Dirk Schadendorf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Dermatology, University Hospital Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Württemberg</state>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Garbe, MD</last_name>
      <phone>+49-7071-2980872</phone>
      <email>studienzentrum-derm-onko@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Claus Garbe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Dermatology, University of Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstanze Spieth, MD</last_name>
      <phone>+49-69-6301-5311</phone>
      <email>konstanze.spieth@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Konstanze Spieth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Dermatology, Medical Center Buxtehude</name>
      <address>
        <city>Buxtehude</city>
        <state>Niedersachsen</state>
        <zip>D-21641</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Mohr, MD</last_name>
      <phone>+49-4161-7036297</phone>
      <email>mohrpe@cs.com</email>
    </contact>
    <investigator>
      <last_name>Peter Mohr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Dermatology, Hildesheim</name>
      <address>
        <city>Hildesheim</city>
        <state>Niedersachsen</state>
        <zip>D-31134</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Tronnier, MD</last_name>
      <phone>+49-05121-894821</phone>
    </contact>
    <investigator>
      <last_name>Michael Tronnier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of. Dermatology, University of Saarland, Homburg</name>
      <address>
        <city>Homburg</city>
        <state>Saaland</state>
        <zip>D-66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Tilgen, MD</last_name>
      <phone>+49-6841-3800</phone>
      <email>hawtil@med-rz-sb.de</email>
    </contact>
    <investigator>
      <last_name>Dorothea Tadler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Dermatology, University Otto von Guericke</name>
      <address>
        <city>Magdeburg</city>
        <state>Saxony-Anhalt</state>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Ulrich, MD</last_name>
      <phone>+49-391-6715428</phone>
      <email>jens.ulrich@medizin.uni-magdeburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Vassiliki Bekou, MD</last_name>
      <phone>+49-391-6715264</phone>
      <email>vassiliki.bekou@medizin.uni-magdeburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Vassiliki Bekou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Dermatology, University of Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Hauschild, MD</last_name>
      <phone>+49-431-596-1613</phone>
      <email>ahauschild@dermatology.uni.kiel.de</email>
    </contact>
    <investigator>
      <last_name>Axel Hauschild, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Dermatology, University of Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>D-23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Krengel, MD</last_name>
      <phone>+49-451-5002517</phone>
      <email>svenkrengel@gm.net</email>
    </contact>
    <investigator>
      <last_name>Sven Krengel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Dermatology, Helios Clinic Erfurt</name>
      <address>
        <city>Erfurt</city>
        <state>Thuringia</state>
        <zip>99012</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruthild Linse, MD</last_name>
      <phone>+49-361-7814300</phone>
    </contact>
    <investigator>
      <last_name>Ruthild Linse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvonne Kellner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Dermatology, University of Jena</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>D-07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kaatz, MD</last_name>
      <phone>+49-3641-937302</phone>
      <email>kaatz@derma.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Martin Kaatz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Dermatology, Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>D-10098</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Trefzer, MD</last_name>
      <phone>+49-30-450518063</phone>
      <email>uwe.trefzer@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Maja Hofmann, MD</last_name>
      <phone>+49-30-450518063</phone>
      <email>maja.hofmann@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Uwe Trefzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Dermatology, Vivantes Clinics</name>
      <address>
        <city>Berlin</city>
        <zip>D-12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Kohl, MD</last_name>
      <phone>+49-30-60043601</phone>
      <email>p.kohl@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Peter Kohl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999 Sep;17(9):2745-51.</citation>
    <PMID>10561349</PMID>
  </reference>
  <reference>
    <citation>Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH, Vukov AM, Rowland KM, Krook JE, Michalak JC. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999 Jun;17(6):1884-90.</citation>
    <PMID>10561229</PMID>
  </reference>
  <reference>
    <citation>Cure H, Souteyrand P, Ouabdesselam R, Roche H, Ravaud A, D'incan M, Viens P, Fargeot P, Lentz MA, Fumoleau P, Hanauske A, Chollet P. Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group. Melanoma Res. 1999 Dec;9(6):607-10.</citation>
    <PMID>10661773</PMID>
  </reference>
  <reference>
    <citation>Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, Heuman R. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997 Feb;8(2):163-8.</citation>
    <PMID>9093725</PMID>
  </reference>
  <reference>
    <citation>Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer. 2001 Apr 20;84(8):1036-42.</citation>
    <PMID>11308250</PMID>
  </reference>
  <reference>
    <citation>Propper DJ, Levitt NC, O'Byrne K, Braybrooke JP, Talbot DC, Ganesan TS, Thompson CH, Rajagopalan B, Littlewood TJ, Dixon RM, Harris AL. Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. Br J Cancer. 2000 Jun;82(11):1776-82.</citation>
    <PMID>10839290</PMID>
  </reference>
  <reference>
    <citation>Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer. 1999 Apr;24(1):17-24.</citation>
    <PMID>10403690</PMID>
  </reference>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2005</study_first_submitted>
  <study_first_submitted_qc>September 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2005</study_first_posted>
  <last_update_submitted>June 20, 2006</last_update_submitted>
  <last_update_submitted_qc>June 20, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2006</last_update_posted>
  <keyword>malignant Melanoma</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Metastasis</keyword>
  <keyword>standard palliative care</keyword>
  <keyword>best supportive care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vindesine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

